Close Menu

NEW YORK – Hologic said this week that the financial outlook for its current fiscal third quarter has improved since April 29 when it reported second-quarter financial results and discussed the impact of the COVID-19 pandemic. In a filing with the US Securities and Exchange Commission, the company said its diagnostics business has "significantly outperformed based on strong sales" of its COVID-19 tests.

Hologic anticipates that diagnostics revenues will grow 20 percent to 25 percent year over year during this fiscal quarter, with more than 75 percent of the quarter completed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.